Cumberland Pharmaceuticals has acquired 1 company.
Cumberland Pharmaceuticals’ largest acquisition to date was in 2018, when it acquired Theravance Biopharma - VIBATIV for $20M. Cumberland Pharmaceuticals has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
1600 West End Avenue, Suite 1300,
Nashville, Tennessee
37203
United States,
(615) 255-0068
www.cumberlandpharma.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2018-11-06 |
Theravance Biopharma, Inc. - VIBATIV · Life Science
South San Francisco, California · www.vibativ.com Theravance Biopharma, Inc. - VIBATIV is patented, FDA approved anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin & skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. |
20 | Divestiture |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
